GSK, XenoPort Unveil Gabapentin Enacarbil Phase II Trial Results
GlaxoSmithKline and XenoPort have reported top-line results from a phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.